viewLexagene Holdings Inc

LexaGene Holdings tackles rapid pathogen detection

LexaGene Holdings (CVE:LXG) President Daryl Rebeck tells Proactive Investors about how the biotech company continues to develop and commercialize pathogen detection devices in the biochemical industry.

Rebeck says pathogens are anything that can make us ill, such as salmonella, E. coli, respiratory diseases, Lyme disease. The instrument LexaGene offers quickly detects multiple pathogens with sensitivity and specificity.

"It's a very easy-to-use instrument," says Rebeck.

The platform could be used in food safety, veterinary diagnostics, water quality monitoring, aquaculture pathogen surveillance, and other markets.

Quick facts: Lexagene Holdings Inc

Price: 0.54 CAD

Market: TSX-V
Market Cap: $46.26 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc named herein, including the promotion by the Company of Lexagene Holdings Inc in any Content on the Site, the Company...



Full interview: Lexagene Develops technology to test for deadly mosquito...

Lexagene (CVE: LXG-OTCQB-LXXGF) Founder and CEO Dr jack Regan joined Steve Darling from Proactive Vancouver on Skype with news the company has used their proprietary technology to develop a detection system for the Eastern Equine Encephalitis or EEE. Regan says that not only can they use the...

on 17/9/19

2 min read